highperformr logo

Alnylam Pharmaceuticals's Overview

Total employees2524
HeadquartersCambridge
Founded2002

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. They are pioneers in translating the science of RNAi into a new class of innovative medicines, targeting a wide range of diseases, including genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. Alnylam aims to address diseases with high unmet medical need, transforming the lives of patients worldwide.

Where is Alnylam Pharmaceuticals's Headquarters?

HQ Function

The Cambridge headquarters serves as the central hub for Alnylam's global operations, including research and development, corporate strategy, executive leadership, and administrative functions.

Notable Features:

The headquarters features state-of-the-art laboratory facilities, modern office spaces designed for collaboration, and is situated within Kendall Square, known for its dense concentration of biotech and pharmaceutical companies and academic institutions like MIT.

Work Culture:

Alnylam fosters an innovative, science-driven, and patient-focused work culture. Collaboration, scientific rigor, and a commitment to making a difference in patients' lives are core tenets of the work environment.

HQ Significance:

Its location in Kendall Square provides Alnylam with unparalleled access to talent, research collaborations, and a vibrant ecosystem of innovation, crucial for its leadership in RNAi therapeutics.

Values Reflected in HQ: The headquarters' design and location reflect Alnylam's commitment to scientific excellence, innovation, collaboration, and its central role in the biotech community.

Location:

Alnylam Pharmaceuticals maintains a significant global presence to support its mission of bringing RNAi therapeutics to patients worldwide. This includes global clinical trial operations spanning numerous countries, regional headquarters and offices in North America, Europe (UK, Switzerland), and Asia-Pacific (Japan), dedicated teams for manufacturing and supply chain logistics, worldwide regulatory affairs management, and commercial teams to launch and support their products in approved markets.

Street Address:

675 West Kendall Street

City:

Cambridge

State/Province:

MA

Country:

USA

Alnylam Pharmaceuticals's Global Presence

Maidenhead, United Kingdom

Address: Alnylam UK, Ltd., Braywick Gate, Braywick Road, Maidenhead, Berkshire, SL6 1DA, UK

To manage and expand Alnylam's presence and product portfolio within the EMEA markets, ensuring patient access to their innovative RNAi therapies.

Zug, Switzerland

Address: Alnylam Switzerland GmbH, Grafenauweg 10, 6300 Zug, Switzerland

To spearhead commercialization and market access efforts in Switzerland and other international territories outside the US and EMEA, contributing to Alnylam's global reach.

Tokyo, Japan

Address: Alnylam Japan KK, Marunouchi Park Building, 2-6-1 Marunouchi, Chiyoda-ku, Tokyo 100-6913, Japan

To establish and grow Alnylam's footprint in the Japanese pharmaceutical market, addressing unmet medical needs with RNAi therapeutics.

Buying Intent Signals for Alnylam Pharmaceuticals

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Alnylam Pharmaceuticals

As of April 2025, Alnylam Pharmaceuticals' leadership includes:

Yvonne Greenstreet, MBChB, MBA - Chief Executive Officer
Akshay Vaishnaw, M.D., Ph.D. - President
Jeff Poulton, MBA - Chief Financial Officer
Pushkal Garg, M.D. - Chief Medical Officer (Note: Transitioned out early 2024, search for current CMO if needed)
Kelley Boucher - Chief Human Resources Officer
Tolga Tanguler - Chief Commercial Officer
Indrani Franchini, J.D., M.P.H. - Chief Legal Officer and Corporate Secretary

Investors of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock, Inc.
State Street Corporation
Fidelity Management & Research Company (FMRCo)
Wellington Management Company LLP
Capital Research Global Investors
Price (T.Rowe) Associates Inc

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits1

Alnylam has seen key leadership appointments and transitions in the past year, notably strengthening its human resources function and experiencing a change in the Chief Medical Officer role.

Departures

Pushkal Garg, M.D., Pushkal Garg, M.D., departed from his role as Chief Medical Officer at Alnylam to become Chief Medical Officer at Vertex Pharmaceuticals.

New Appointments:

Kelley Boucher, Kelley Boucher joined Alnylam as Chief Human Resources Officer, bringing over 20 years of experience in global HR.

Technology (Tech Stack) used by Alnylam Pharmaceuticals

Discover the tools Alnylam Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Alnylam Pharmaceuticals Email Formats and Examples

Alnylam Pharmaceuticals commonly uses the first initial followed by the last name for their email addresses. For example, Jane Doe would likely be jdoe@alnylam.com.

[first_initial][last]@alnylam.com

Format

jdoe@alnylam.com

Example

90%

Success rate

News and media

Alnylam PharmaceuticalsMay 2, 2024

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam announced its Q1 2024 financial results, highlighting product revenue growth and advancements in its clinical pipeline, including progress with zilebesiran for hypertension....more

Alnylam PharmaceuticalsMarch 26, 2024

Alnylam Pharmaceuticals Announces Publication of Complete Results from KARDIA-1 Phase 2 Study of Zilebesiran in The New England Journal of Medicine

Alnylam announced the full results from its KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic for hypertension, were published in NEJM, showing positive efficacy and safety....more

Alnylam PharmaceuticalsMarch 4, 2024

Alnylam Reports Positive Topline Results from KARDIA-2 Phase 2 Study of Zilebesiran in Patients with Uncontrolled Hypertension Despite Treatment with Standard of Care Antihypertensive Medications

Alnylam shared positive topline results from the KARDIA-2 Phase 2 study, demonstrating zilebesiran's potential in treating uncontrolled hypertension when added to standard antihypertensive treatments....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Alnylam Pharmaceuticals, are just a search away.